Alterity Therapeutics Phase 2 Data Monitoring Committee : vi

ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia and SAN FRANCISCO, July 26,...

Related Keywords

Melbourne , Victoria , Australia , San Francisco , California , United States , David Stamler , Remy Bernarda , Hannah Howlett , Drug Administration , European Commission , Data Monitoring Committee , Alterity Therapeutics , Nasdaq , Complete Enrollment , Line Data Expected , Chief Executive Officer , Multiple System Atrophy , System Atrophy , Media Contacts , Securities Act ,